Compounds > sb 203580
Page last updated: 2024-09-05

sb 203580 and purvalanol a

sb 203580 has been researched along with purvalanol a in 5 studies

Compound Research Comparison

Studies
(sb 203580)		Trials
(sb 203580)		Recent Studies (post-2010)
(sb 203580)		Studies
(purvalanol a)		Trials
(purvalanol a)		Recent Studies (post-2010) (purvalanol a)
3,48941,13786042

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)purvalanol a (IC50)
Cyclin-T1Homo sapiens (human)0.0497
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.0193
Serine/threonine-protein kinase PAK 4Homo sapiens (human)0.13
G1/S-specific cyclin-E2Homo sapiens (human)0.035
Cyclin-dependent kinase 1Saccharomyces cerevisiae S288C0.08
Insulin receptorHomo sapiens (human)5
Cyclin-dependent kinase 1Homo sapiens (human)0.0968
Cyclin-dependent kinase 4Homo sapiens (human)0.6808
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.1833
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.1026
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)9
Cyclin-A2Homo sapiens (human)0.0556
cAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)9
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)9
G1/S-specific cyclin-D1Homo sapiens (human)0.85
G1/S-specific cyclin-E1Homo sapiens (human)0.035
Cyclin-dependent kinase 2Homo sapiens (human)0.0617
Mitogen-activated protein kinase 3 Homo sapiens (human)9
Cyclin-dependent kinase 7Homo sapiens (human)0.0497
Cyclin-dependent kinase 9Homo sapiens (human)0.0497
Cyclin-HHomo sapiens (human)0.0497
Cyclin-A1Homo sapiens (human)0.05
Cyclin-dependent-like kinase 5 Homo sapiens (human)0.0623
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)0.3
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)0.0623
Cdc2Patiria pectinifera0.27
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.0193

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Angiolini, M; Ardini, E; Casale, E; Zuccotto, F1
Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A1
Bharate, SB; Raghuvanshi, R1

Reviews

1 review(s) available for sb 203580 and purvalanol a

ArticleYear
Through the "gatekeeper door": exploiting the active kinase conformation.
    Journal of medicinal chemistry, 2010, Apr-08, Volume: 53, Issue:7

    Topics: Drug Design; Humans; Protein Kinase Inhibitors; Protein Kinases; Substrate Specificity

2010

Other Studies

4 other study(ies) available for sb 203580 and purvalanol a

ArticleYear
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    The Biochemical journal, 2013, Apr-15, Volume: 451, Issue:2

    Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase

2013
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022